Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden

Harm Reduction Journal

Björn Johnson¹  Torkel Richert¹ 

[1] Department of Social Work, Malmö University, Malmo, Sweden

关键词: Barriers to treatment;    Opioid substitution treatment;    Self-treatment;    Buprenorphine;    Methadone;    Heroin;    Illicit use;   

Others  :  1133809
DOI  :  10.1186/s12954-015-0037-2

 received in 2014-10-20, accepted in 2015-01-20,  发布年份 2015

【 摘 要 】

Background

It is well known that illicit use of methadone and buprenorphine is common among people with an opioid dependence. Less notice has been taken of the fact that these substances are also used for extended periods of self-treatment, as a way of handling barriers to OST. In this study, motives for self-treatment are investigated, as well as attitudes and perceived barriers to OST among drug users with an opioid dependence in Sweden.

Method

The study is based on qualitative research interviews with 27 opioid users who have treated themselves with methadone or buprenorphine for a period of at least three months.

Results

The duration of self-treatment among the interviewees varied from 5 months to 7 years. Self-treatment often began as a result of a wish to change their life situation or to cut back on heroin, in conjunction with perceived barriers to OST. These barriers consisted of (1) difficulties in gaining access to OST due to strict inclusion criteria, limited access to treatment or a bureaucratic and arduous assessment process, (2) difficulties remaining in treatment, and (3) ambivalence toward or reluctance to seek OST, primarily due to a fear of stigmatization or disciplinary action. Self-treatment was described as an attractive alternative to OST, as a stepping stone to OST, and as a way of handling waiting lists, or as a saving resource in case of involuntary discharge.

Conclusion

Illicit use of methadone and buprenorphine involve risks but may also have important roles to play for users who are unwilling or not given the opportunity to enter OST. A restrictive and strict rehabilitation-oriented treatment model may force many to manage their own treatment. More generous inclusion criteria, a less complex admission process, fewer involuntary discharges, and less paternalistic treatment may lead to increasing numbers seeking OST. Control measures are necessary to prevent diversion and harmful drug use but must be designed in such a way that they impose as few restrictions as possible on the daily life of patients.

【 授权许可】

   
2015 Richert and Johnson; licensee BioMed Central.

【 参考文献 】

• [1]Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;10.
• [2]Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2.
• [3]Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3.
• [4]Johnson B: Methadone and buprenorphine: attractive on the street and outside treatment programs. Lakartidningen 2011, 108(45):2309-11.
• [5]Yokell MA, Zaller ND, Green TC, Rich JD: Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev 2011, 4(1):28-41.
• [6]Seymour A, Black M, Jay J, Cooper G, Weir C, Oliver J: The role of methadone in drug-related deaths in the west of Scotland. Addiction 2003, 98(7):995-1002.
• [7]Morgan O, Griffiths C, Hickman M: Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993–2004. Int J Epidemiol 2006, 35(6):1579-85.
• [8]Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I: Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007, 102(3):406-12.
• [9]Strang J, Hall W, Hickman M, Bird SM: Impact of supervision of methadone consumption on deaths related to methadone overdose. BMJ 1993, 341:c4851.
• [10]Madden ME, Shapiro SL: The methadone epidemic: methadone-related deaths on the rise in Vermont. Am J Forensic Med Pathol 2011, 32(2):131-5.
• [11]Harris M, Rhodes T: Methadone diversion as protective strategy: the harm reduction potential of ‘generous constraints’. Int J Drug Policy 2012, 24(6):e43-50.
• [12]Bridge TP, Fudala PJ, Herbert S, Leiderman DB: Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend 2003, 2:S79-85.
• [13]Håkansson A, Medvedeo A, Andersson M, Berglund M: Buprenorphine misuse among heroin and amphetamine users in Malmö, Sweden: purpose of misuse and route of administration. Eur Addict Res 2007, 13(4):207-15.
• [14]Monte A, Mandell T, Wilford B, Tennyson J, Boyer E: Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis 2009, 28(3):226-31.
• [15]Richert T, Johnson B: Illicit use of methadone and buprenorphine among adolescents and young adults in Sweden. Harm Reduct J 2013, 10:27. BioMed Central Full Text
• [16]Mitchell SG, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, Ruhf A, et al.: Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict 2009, 18(5):346-55.
• [17]Schuman-Olivier Z, Albanese M, Nelson SE, Roland L, Puopolo F, Klinker L, et al.: Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat 2010, 39(1):41-50.
• [18]Lofwall MR, Havens JR: Inability to access buprenorphine treatment as risk factor for using diverted buprenorphine. Drug Alcohol Depend 2012, 126:379-83.
• [19]Peterson JA, Schwartz RP, Mitchell SG, Reisinger HS, Kelly SM, O’Grady KE, et al.: Why don’t out-of-treatment individuals enter methadone treatment programs? Int J Drug Policy 2010, 21(1):36-42.
• [20]Stöver H: Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res 2011, 17:44-54.
• [21]Schmidt CS, Schulte B, Wickert C, Thane K, Kuhn S, Verthein U, et al.: Non-prescribed use of substitution medication among German drug users: prevalence, motives and availability. Int J Drug Policy 2013, 24(6):e111-4.
• [22]Kakko J, Svanborg KD, Kreek MJ, Heilig M: 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003, 361(9358):662-8.
• [23]Johnson B: Metadon på liv och död. En bok om narkomanvård och narkotikapolitik i Sverige. Studentlitteratur, Lund; 2005.
• [24]Kakko J, Grönbladh L, Svanborg KD, von Wachenfeldt J, Rück C, Rawlings B, et al.: A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007, 164(5):797-803.
• [25]Ekendahl M: The limits of legitimacy: service providers’ views on maintenance treatment in Sweden. Addic Res Theory 2011, 19(5):427-37.
• [26]Johnson B: Policyspridning som översättning. Den politiska översättningen av metadonbehandling och husläkare i Sverige. Arbetslivsinstitutet, Malmö; 2003.
• [27]Johnson B: After the storm: developments in maintenance treatment policy and practice in Sweden 1987–2006. In On the margins: Nordic alcohol and drug treatment 1885–2007. Edited by Edman J, Stenius K. NAD, Helsingfors; 2007.
• [28]Ekendahl M: The construction of maintenance treatment legitimacy: a discourse analysis of a policy shift. Evid Policy 2009, 5:247-65.
• [29]SOSFS 2009:27. Socialstyrelsens föreskrifter och allmänna råd om läkemedelsassisterad behandling vid opiatberoende.
• [30]Johnson B: Vetenskap och beprövad erfarenhet eller ett blött finger i luften? In Med narkotikan som följeslagare: femton texter till Bengt Svensson. Edited by Johnson B, Lalander P. Malmö University, Malmö; 2013.
• [31]Sjölander J, Johnson B. Tillgängligheten till läkemedelsassisterad behandling i Sverige—en uppföljning. Malmö högskola: Malmö; 2009.
• [32]SOSFS 2004:8. Socialstyrelsens föreskrifter och allmänna råd om läkemedelsassisterad behandling vid opiatberoende.
• [33]Johnson B, Richert T. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors. Int J Drug Policy, doi:10.1016/j.drugpo.2014.10.003.
• [34]Svensson B, Andersson M: Involuntary discharge from medication-assisted treatment for people with a heroin addiction—patients’ experiences and interpretations. Nord Stud Alcohol Dr 2012, 29(2):173-93.
• [35]Fugelstad A, Johansson LA, Thiblin I: Allt fler dör av metadon (More and more people die from methadone). Lakartidningen 2010, 107(18):1225-8.
• [36]Reunanen A: Den livslånga avgiftningen. KRIS, Stockholm; 2012.
• [37]Spunt B, Hunt DE, Lipton DS, Goldsmith DS: Methadone diversion: a new look. J Drug Issues 1986, 16(4):569-83.
• [38]Antoniusson E-M. Illegal Subutexanvändning. Mobilisering mot narkotika: Stockholm; 2007.
• [39]Roche A, McCabe S, Smyth BR: Illicit methadone use and abuse in young people accessing treatment for opiate dependence. Eur Addict Res 2008, 14:219-25.
• [40]Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication. J Addict Dis, doi:10.1080/10550887.2014.975617.
• [41]Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective. J Psychoactive Drugs. 46(5):427–35.
• [42]Milroy CM, Forrest ARW: Methadone deaths: a toxicological analysis. J Clin Pathol 2000, 53(4):277-81.
• [43]Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ: Does high-dose buprenorphine cause respiratory depression? Toxicol Rev 2006, 25(2):79-85.
• [44]Valentine K: Evidence, values and drug treatment policy. Critical Social Policy 2009, 29:443-64.
• [45]Svensson B: Narkotikapolitik och narkotikadebatt. Studentlitteratur, Lund; 2012.
• [46]Richert T. Overdoses, income strategies and risk handling—living conditions for people who inject illegal drugs. PhD thesis. Malmö University; 2014.
• [47]Deering DE, Sheridan J, Sellman JD, Adamson SJ, Pooley S, Robertson R, et al.: Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav 2011, 48(10):1244-57.
• [48]Preble E, Miller T: Methadone, wine and welfare. In Street Ethnography. Edited by Weppner R. Sage Publications, Beverly Hills, CA; 1977.
• [49]Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B: “It takes your heart”: the image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict 1985, 20(11&12):1751-71.
• [50]Bourgois P: Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry 2000, 24(2):165-95.
• [51]Murphy S, Irwin J: “Living with the dirty secret”: problems of disclosure for methadone maintenance clients. J Psychoactive Drugs 1992, 24(3):257-64.
• [52]Gerra G, Saenz E, Busse A, Maremmani I, Ciccocioppo R, Zaimovic A, et al.: Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(2):483-9.
• [53]Bell J, Shanahan M, Mutch C, Rea F, Ryan A, Batey R, et al.: A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007, 102(12):1899-907.
• [54]Öhlin L, Tätting P, Fridell M: Substitutionsbehandling med drogfri kontraktsvård. Så gick det.ss 2013:110.
• [55]Petersson F: Excusing exclusion: accounting for rule-breaking and sanctions in a Swedish methadone clinic. Int J Drug Policy 2013, 24:e99-104.
• [56]Grönbladh L, Öhlund LS, Gunne LM: Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990, 82:223-7.
• [57]Clausen T, Åsland R, Kristensen Ø: Pasienter som avbryter LAR-behandling—hvordan går det med dem? Tidsskr Nor Laegeforen 2014, 134(16):1548-9.
• [58]Hirchman AO: Exit, voice, and loyalty: responses to decline in firms, organizations, and states. Harvard University Press, Cambridge, MA; 1970.
• [59]Romelsjö A, Engdahl B, Stenbacka M, Fugelstad A, Davstad I, Leifman A, et al.: Were the changes to Sweden’s maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity? Addiction 2010, 105(9):1625-32.